Does the therapist relationship drive psilocybin's effect on hard-to-treat depression?

The question

In psilocybin treatment for depression that has not responded to other treatments, how much does the bond between patient and the people supporting them matter, compared with the drug experience itself?

What they did

Researchers re-analyzed data from a multicentre phase II randomized trial. They looked at 79 people with treatment-resistant depression who received a 25 mg dose of psilocybin with monitoring and support. Before dosing, participants rated their relationship with their support team using a standard questionnaire. They also rated their drug experience afterwards, including feelings of emotional breakthrough, a sense of boundlessness, and changes in what they saw and heard. Depression was measured with a clinician-rated scale at the start and at week 3.

What they found

Improvement in depression at week 3 was only weakly linked to the pre-dosing therapeutic relationship (correlation -0.178). It was much more strongly linked to the drug experience itself: emotional breakthrough (-0.637), oceanic boundlessness (-0.508) and visual changes (-0.516). In the path analysis, the therapeutic relationship had no statistically notable direct effect on depression scores, but it did predict stronger psychedelic experiences (oceanic boundlessness β = 0.28, visual changes β = 0.27, auditory changes β = 0.25). Only one indirect route from the relationship to depression outcome reached nominal significance (through visual changes, β = -0.15), while the drug experience measures showed stronger direct effects on outcome (for example emotional breakthrough β = -0.59).

The fine print

This was a post-hoc analysis, meaning the questions were asked after the trial ended, and the results are described as only “nominally” significant, so they were not corrected for testing many relationships at once. The sample was 79 people, follow-up here was just three weeks, and everyone received support, so there was no comparison group without support. The alliance was measured before dosing only, and these are correlations, so they cannot prove what caused what. This summary is based on the abstract alone.

What it means

In this analysis, the quality of the patient-therapist relationship seemed to help shape the psilocybin experience, but the intensity of that experience was more closely tied to depression improvement than the relationship itself was.

Evidence grade: Low. This is a post-hoc statistical analysis of data from one arm of a phase II trial, not a test the trial was designed to answer.

This summary is based on the study’s published abstract.